MinireviewShort-chain acyl-coenzyme A dehydrogenase deficiency
Section snippets
Clinical presentation
The first published case of what was initially considered to be SCADD was a 53-year-old woman with progressive myopathy whose symptoms began in her forties [13]. She was later felt to have a multiple acyl-CoA dehydrogenation defect [14]. True SCADD was first reported in two neonates who were found to have increased urinary ethylmalonate excretion; the diagnosis was confirmed enzymatically in skin fibroblasts [15]. One of these infants died of overwhelming neonatal acidosis as would be typical
Molecular genetics and functional implications of SCAD mutations
Understanding the molecular basis of SCADD is key to deciphering its variable clinical picture. The SCAD gene is located on chromosome 12q22 and is approximately 13 kb long with 10 exons and 1236 nucleotides of coding sequence [26], [27]. SCAD, like all of the ACADs, is a flavoprotein that is synthesized in the cytosol as a precursor and transported to the mitochondria for further processing by proteolytic cleaving of an N-terminal mitochondrial targeting sequence into a mature form [27], [28].
Pathophysiology of SCADD
Most individuals have not presented with the classic picture of hypoketotic hypoglycemia, recurrent rhabdomyolysis, or cardiomyopathy that characterize many other fatty acid oxidation disorders. A 14 month old with SCADD was reported to have hypoglycemia, but ketonuria was also present, suggesting that ketone body formation is not significantly impacted in SCADD [37]. One explanation for the lack of classical biochemical findings is that since SCAD is only needed at the end of the β-oxidation
Diagnosis of SCADD
Biochemical markers of SCADD include increased urinary EMA and butyrylglycine, increased plasma butyrylcarnitine, and decreased SCAD activity in skin fibroblasts or muscle, though some enzymatic assays are not sufficiently sensitive for reliable measurements [11]. During times of metabolic stress, methylsuccinate (the hydrolyzed product of isomerization of ethylmalonyl-CoA by methylmalonyl-CoA isomerase) may also be excreted in the urine [14], [15]. Some patients have been reported to have low
Management
Little firm data exists on the appropriate therapy for SCADD and there is not a consensus on the need to treat it. Chronic management of SCADD, if institutued, should be similar to other fatty acid oxidation disorders, focusing on decreasing catabolic drive as well as providing alternative sources of energy. During acute crises, intravenous fluids with high dextrose concentrations (usually at least 10% to give 8–10 mg/kg/min of glucose intake) with or without intralipids can be used to reverse
Discussion
SCADD demonstrates several of the clinical and public policy issues currently facing many inborn errors of metabolism identified by expanded newborn screening with tandem mass spectrometry, including deficiency of short/branched chain- and isobutyryl-CoA dehydrogenases as well as 3-methylcrotonyl-CoA carboxylase. Issues surrounding these disorders echo similar problems faced in earlier decades of newborn screening with diseases such as histidinemia and the Duarte variant galactosemia.
Acknowledgments
JV was funded in part by NIH grant R01-DK54936 and the Mathew Fisch Fund of the Children’s Hospital of Pittsburgh Foundation.
References (51)
- et al.
Riboflavin and rat hepatic cell structure and function
J. Biol. Chem.
(1979) - et al.
FAD-dependent regulation of transcription, translation, post-translational processing, and post-processing stability of various mitochondrial acyl-CoA dehydrogenases and of electron transfer flavoprotein and the site of holoenzyme formation
J. Biol. Chem.
(1992) - et al.
Biosynthesis of four rat liver mitochondrial acyl-CoA dehydrogenases; import into mitochondria and processing of their precursors in a cell-free system and in cultured cells
Arch. Biochem. Biophys.
(1987) - et al.
Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-CoA, short chain acyl-CoA, and isovaleryl CoA dehydrogenases: sequence homology of four enzymes of the acyl-CoA dehydrogenase family
J. Biol. Chem.
(1989) - et al.
The frequency of short-chain acyl-CoA dehydrogenase gene variants in the US population and correlation with the C4-acylcarnitine concentration in newborn blood spots
Mol. Genet. Metab.
(2003) - et al.
Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency
J. Pediatr.
(1995) - et al.
Short-chain acyl-CoA dehydrogenase gene mutation (319C>T) presents with clinical heterogeneity and is candidate founder mutation in Ashkenazi Jewish population
Mol. Genet. Metab.
(2008) - et al.
Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency
J. Pediatr.
(2001) - et al.
Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms
Mol. Genet. Metab.
(2008) - et al.
Clinical Outcomes of infants with short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD) detected by newborn screening
Mol. Genet. Metab.
(2008)
Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with acetoacetyl-CoA
J. Biol. Chem.
Misfolding, degradation, and aggregation of variant proteins; the molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency
J. Biol. Chem.
Synergistic heterozygosity in mice with inherited enzyme deficiencies of mitochondrial fatty acid beta-oxidation
Mol. Genet. Metab.
Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways
Mol. Genet. Metab.
Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency
Genet. Med.
A profile of cerebral and hepatic carnitine, ammonia, and energy metabolism in a model of organic aciduria: BALB/cByJ mouse with short chain acyl-CoA dehydrogenase deficiency
Biochem. Med. Metab. Biol.
Transient organic aciduria and persistent lactic acidemia in a patient with short-chain acyl-coenzyme A dehydrogenase deficiency
J. Pediatr.
Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children
J. Pediatr.
A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric academia diagnosed by newborn screening
Am. J. Hum. Genet.
Riboflavin deficiency and β-oxidation systems in rat liver
Lipids
Evolution of the acyl-CoA dehydrogenase/oxidase superfamily
Prog. Clin. Biol. Res.–New Dev. Fatty Acid Oxidat.
Mechanistic Studies with general acyl-CoA dehydrogenase and butyryl-CoA dehydrogenase: evidence for the transfer of the beta-hydrogen to the flavin N(5)-position as a hydride
Biochemistry
Structure and mechanism of action of the acyl-CoA dehydrogenases
FASEB
The Acyl-CoA Dehydrogenases: Some Mechanistic Aspects
Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase
Pediatr. Res.
Cited by (76)
Multiplexed LC-MS/MS analysis of methylsuccinic acid, ethylmalonic acid, and glutaric acid in plasma and urine
2022, Analytical BiochemistryCitation Excerpt :Due to a few published studies of sample analysis in human plasma and urine for MSA, EMA, and GA, the clinical reference used by the Mayo Clinical Laboratory (MCL) was applied in assessment for comparison purposes. Diagnosis algorithms for these rare metabolic diseases indicated that both elevated levels of MSA and EMA in plasma were observed for SCADD patients and only elevated EMA in plasma was found for EE patients [1,4,8,10]. Raised levels of MSA, EMA, and GA in urine were noticed in patients with GAD type II [12].
Flavin adenine dinucleotide ameliorates hypertensive vascular remodeling via activating short chain acyl-CoA dehydrogenase
2020, Life SciencesCitation Excerpt :Study showed that presence of Caveolin-1 control the vascular permeability, accommodate eNOS activation and stimulate apoptosis [19–21]. Some studies have shown that FAD, clinically, applied to the assistant treatment of short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD), which can stabilize the structure and inhibit protease-mediated degradation of SCAD [22–25]. SCAD expression in rat mitochondria was controlled by FAD, which not only regulated the gene, but also the protein expression [26–28].
Altered mitochondrial proteome and functional dynamics in patients with rheumatoid arthritis
2020, MitochondrionCitation Excerpt :Apart from glucose, fatty acids are also a source of energy. CPT1a (Walker et al., 2014) and ACADS is involved in fatty acid β-oxidation, deficiency of which causes altered β-oxidation process (Jethva et al., 2008). BDH1 is involved in ketone body metabolism which also functions as a source of energy and its downregulation may cause reduced production of energy from ketone bodies (Huang et al., 2016).
Mitochondrial Hepatopathies: Disorders of Fatty Acid Oxidation and the Respiratory Chain
2020, Pediatric Gastrointestinal and Liver Disease, Sixth EditionOrganic Acidemias and Disorders of Fatty Acid Oxidation
2020, Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics: Metabolic DisordersDisorders of lipid metabolism
2020, Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Volume 1